What does fair value of common stock grant date mean?

The estimated fair market value per share of common stock on the date equity awards are granted to participants. This value serves as the basis for calculating the total compensation expense to be recognized over the vesting period.

Citius Oncology, Inc. CTOR Fair Value Of Common Stock Grant Date

Fair Value Of Common Stock Grant Date at other companies

BKBK

$25M—

KKR & Co.KKR

$79.940.0%

BeldenBDC

$7.42M+112%

General MotorsGM

$50.88+21.8%

Bank of Marin BancorpBMRC

$8.490.0%

Auburn National BancorporationAUBN

28.3—

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept ctor:FairValueOfCommonStockGrantDate.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s fair value of common stock grant date.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s fair value of common stock grant date?: Citius Oncology, Inc. (CTOR) reported fair value of common stock grant date of $20.3M in Q3 2025.
What does fair value of common stock grant date mean?: The estimated fair market value per share of common stock on the date equity awards are granted to participants. This value serves as the basis for calculating the total compensation expense to be recognized over the vesting period.